Search company, investor...

Action Pharma

Founded Year



Series B | Alive

Total Raised


Last Raised

$19.95M | 15 yrs ago

About Action Pharma

a biopharmaceutical company founded in 2000 and located in Denmark The company's main strategy is to bring drug candidates rapidly from pre-clinical development into clinical trials for subsequent partnering.The goal is to bring one drug candidate into clinical development per year and currently two lead candidates are in clinical development. The company plan to seek partners for late clinical development and commercialisation of the company's drug candidates after successful development in phase I or II by partnering with major biotech and pharmaceutical companies.

Headquarters Location

Næsseslottet Dronninggaards Alle 136


Missing: Action Pharma's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Action Pharma's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Action Pharma

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Action Pharma is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Latest Action Pharma News

Action Pharma raises fresh capital from new and existing investors - Invest in Denmark

Jun 27, 2013

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. × × About Cookies Information about cookies A cookie is a small text file, which is placed on your computer or other devices. It makes it possible for us to recognize your computer and gather information about which pages and functions are visited with your computer. Cookies contain only anonymous information. Cookies are used by most websites and are in many cases essential for the website to work properly. Cookies on this website We use cookies on this website for various purposes related to functionality, web analysis and marketing. We use cookies primarily to gather statistics about the users’ visits. The information gathered is used to improve the user experience on our website. You can read more about the cookies we use under the three tabs. The cookies are divided into categories and you will find information about their name, expiration, purpose and company. No to cookies If you wish to decline the use of cookies now or in the future, you can change the permission in your browser settings. You block for the use of cookies from this and other websites by adding the domain under settings in your browser. Read more about how you control cookies in your browser on What happens if I say no to cookies? If you choose to decline cookies in your browser, your device will not be tracked when you browse the internet. However, please note that by declining cookies you will automatically also not allow a lot of functionality on various websites and they may not work correctly. Why inform about cookies? We inform about cookies because we are required to inform about them as described in The Privacy and Electronic Communications (EC Directive) (Amendment) Regulations 2011 (pdf). Close

Action Pharma Frequently Asked Questions (FAQ)

  • When was Action Pharma founded?

    Action Pharma was founded in 2000.

  • What is Action Pharma's latest funding round?

    Action Pharma's latest funding round is Series B.

  • How much did Action Pharma raise?

    Action Pharma raised a total of $19.95M.

  • Who are the investors of Action Pharma?

    Investors of Action Pharma include Global Life Science Ventures, Innovations Kapital, Inventure, SLS Invest and Sunstone Capital.

  • Who are Action Pharma's competitors?

    Competitors of Action Pharma include ChemoCentryx, Oligomerix, Innate Pharma, ForSight VISION4, CMC Biologics and 15 more.

Compare Action Pharma to Competitors

Angel Biotechnology

Angel Biotechnology Holdings PLC (AIM: ABH) is a world class, contract biomanufacturing company offering process development services and pre-GMP and cGMP manufacturing to support biotechnology and pharmaceutical companies worldwide. Angel's principal activity is the manufacture and supply of materials for use in early stage drug development and pre-clinical studies, along with drug product and CMC documentation for Phases I, II and III clinical trials and the manufacture of licensed drugs or vaccines. nnAngel is managed by a team that has more than 100 years' combined experience in pharmaceutical and biopharmaceutical manufacture, gained in companies such as Glaxo and Serologicals Inc. nnAngel operates out of Pentlands Science Park, near Edinburgh.

Oligomerix Logo

Oligomerix is a clinical-stage biotechnology company. It focuses on developing disease-modifying therapeutics for neurodegenerative diseases characterized by the aberrant tau protein, ranging from tauopathies such as progressive supranuclear palsy and frontotemporal dementia to Alzheimer’s disease. The firm serves clients in the healthcare sector. Oligomerix was founded in 2006 and is based in West Harrison, New York.


BioVascular Inc. is a privately held biotechnology company that develops drugs and devices for the control of intimal hyperplasia associated with vascular procedures and control of risk factors associated with cardiovascular morbidity and mortality. BioVascular's lead product, saratin, is a polypeptide produced by recombinant means in yeast. This product was licensed from Merck, KGaA in 2005. BioVascular began human clinical trials of saratin for hemodialysis graft access in late 2006 and will begin human trials in the treatment of peripheral artery grafts in early 2007. BioVascular's second product utilizes a mechanism for reduction of a recently defined cardiovascular risk factor. This product will enter human studies in mid 2007.

Cerecin Logo

Cerecin is a biopharmaceutical company with a drug for Alzheimer's in late-stage clinical testing. Cerecin's pipeline consists of therapeutic drugs and medical foods for neurodegenerative diseases such as Alzheimer's, Parkinson's, and Age-Associated Memory Impairment. The company was founded in 2001 and is based in Singapore.


REGiMMUNE is a biotechnology company focused on the discovery, development and commercialization of immune regulatory therapeutics to treat conditions such as allergies, autoimmune diseases and inflammatory disorders.


Argenes, Inc. is a Japanese bio-venture established in April 2004 focusing primarily on the development of biopharmaceuticals and molecular targeting therapeutics, including anti-rheumatoid arthritis (RA), and anti-osteoarthritis. Currently, the company's most innovatory prospective candidate for the treatment of RA is the drug anti-Fas mAb ARG098. The company operate preclinical and clinical studies as well as manufacturer pharmaceuticals through managing of CRO and CMO. At Argenes, Inc. the company continually seek to expand globally through creating alliances and through licensing out development rights and marketing rights.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.